
Biliary Tract Cancer (BTC)- Pipeline Insight, 2025
Description
DelveInsight’s, “Biliary Tract Cancer(BTC)- Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Biliary Tract Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Biliary Tract Cancer: Overview
Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. Biliary tract cancer tumor arise from epithelial cells lining the biliary tract, which consists of the intrahepatic bile duct, extrahepatic bile duct, gall bladder, and ampulla of Vater. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.
""Biliary Tract Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Biliary Tract Cancer pipeline landscape is provided which includes the disease overview and Biliary Tract Cancer treatment guidelines. The assessment part of the report embraces, in depth Biliary Tract Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Biliary Tract Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Biliary Tract Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Biliary Tract Cancer Emerging Drugs
Further product details are provided in the report……..
Biliary Tract Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Biliary Tract Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Biliary Tract Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Biliary Tract Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Biliary Tract Cancer drugs.
Biliary Tract Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Biliary Tract Cancer: Overview
Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. Biliary tract cancer tumor arise from epithelial cells lining the biliary tract, which consists of the intrahepatic bile duct, extrahepatic bile duct, gall bladder, and ampulla of Vater. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.
""Biliary Tract Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Biliary Tract Cancer pipeline landscape is provided which includes the disease overview and Biliary Tract Cancer treatment guidelines. The assessment part of the report embraces, in depth Biliary Tract Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Biliary Tract Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Tract Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Biliary Tract Cancer.
This segment of the Biliary Tract Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Biliary Tract Cancer Emerging Drugs
- MRG 002: Miracogen
- Disitamab vedotin: Yantai Rongchang Pharmaceutical
- Envafolimab: Alphamab Oncology
- DKN-01: Leap Therapeutics
Further product details are provided in the report……..
Biliary Tract Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Biliary Tract Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Biliary Tract Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Biliary Tract Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Biliary Tract Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Biliary Tract Cancer drugs.
Biliary Tract Cancer Report Insights
- Biliary Tract Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Biliary Tract Cancer drugs?
- How many Biliary Tract Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Biliary Tract Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Biliary Tract Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Biliary Tract Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Yantai Rongchang Pharmaceutical
- RemeGen
- EMD Serono
- SMT bio Co., Ltd.
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- InnoPharmax Inc.
- Lee's Pharmaceutical Limited
- Hoffmann-La Roche
- Shanghai Miracogen Inc.
- Zymeworks Inc.
- Bristol-Myers Squibb
- Eli Lilly and Company
- Ipsen
- Threshold Pharmaceuticals
- Leap Therapeutics
- Hutchison Medipharma Limited
- Array BioPharma
- Redx Pharma Plc
- Compass Therapeutics
- Lee's Pharmaceutical Limited
- Disitamab vedotin
- Bintrafusp alfa
- SMT-NK
- HA121-28
- D07001
- ZKAB001
- Atezolizumab
- MRG003
- ZW25
- Nivolumab
- Ramucirumab
- Nanoliposomal Irinotecan
- TH-302
- DKN-01
- Surufatinib
- Tucatinib
- RXC004
- CTX-009
- Envafolimab
- ZKAB001
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Biliary Tract Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Biliary Tract Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Envafolimab: Alphamab Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- Comparative Analysis
- SMT-NK: SMT bio Co., Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- HA121-28: CSPC ZhongQi Pharmaceutical Technology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ZKAB001: Lee's Pharmaceutical Limited
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Biliary Tract Cancer Key Companies
- Biliary Tract Cancer Key Products
- Biliary Tract Cancer- Unmet Needs
- Biliary Tract Cancer- Market Drivers and Barriers
- Biliary Tract Cancer- Future Perspectives and Conclusion
- Biliary Tract Cancer Analyst Views
- Biliary Tract Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.